

P1 1071434

10/524473

REC'D 03 OCT 2003

WIPO

PCT

17 FEB 2005

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

September 27, 2003

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/404,183

FILING DATE: August 16, 2002

RELATED PCT APPLICATION NUMBER: PCT/US03/25674

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

M. Sias
M. SIAS
Certifying Officer

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

BEST AVAILABLE

CERTIFIED COPY OF
PRIORITY DOCUMENT

08/16/02
Jc901 U.S. PTO

Please type a plus sign (+) inside this box → ☐ +

08-19-02


Approved for use through 10/31/2002 OMB 0651-0032

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
Leonard D. Bertrand		Kohn Saunier		Athens, Ohio Athens, Ohio	
<input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (280 characters max)					
HEPATITIS C VIRAL-LIKE PARTICLE PURIFICATION					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input checked="" type="checkbox"/> Customer Number		24024			
OR		Type Customer Number Here		24024 PATENT TRADEMARK OFFICE	
<input type="checkbox"/> Firm or Individual Name					
Address					
Address					
City		State		ZIP	
Country		Telephone		Fax	
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification		Number of Pages 47		<input type="checkbox"/> CD(s), Number	
<input checked="" type="checkbox"/> Drawing(s)		Number of Sheets 22		<input checked="" type="checkbox"/> Other (specify)	
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76		Return receipt postcard			
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/> Applicant claims small entity status		FILING FEE AMOUNT			
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees		\$80.00			
<input type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number					
<input type="checkbox"/> Payment by credit card Form PTO-2038 is attached					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

Respectfully submitted,

SIGNATURE

Pamela A. Docherty

PRINTED NAME: Pamela A. Docherty

TELEPHONE 216-622-8416

Date

August 16, 2002

REGISTRATION NO.
(if appropriate)

40,591

Docket Number

27211/04058

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

EXPRESS MAILING CERTIFICATE

"EXPRESS MAIL" Mailing Label No: EL084651309US
Date of Deposit: August 16, 2002

I hereby certify that this application is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Typed or printed name of person signing this certificate:

BILL PIATAK

Signed: BILL PIATAK

Atty. Docket No. 27211/04058

HEPATITIS C VIRAL-LIKE PARTICLE PURIFICATION

This invention is supported, at least in part, by the National Institutes of Health, USA.
The U.S. government has certain rights in the invention.

FIELD OF THE INVENTION

The invention relates to hepatitis C virus-like particles, a method for purifying the particles, methods of screening for the presence of hepatitis C, methods for screening compounds that interfere with binding and/or internalization of the virus-like particles to/into host cells, cell lines used for screening of the compounds, methods for detecting and identifying cellular receptors for hepatitis C virus and use of the hepatitis C virus-like particles as vaccines.

BACKGROUND

Hepatitis C Virology

Hepatitis C virus (HCV) is an enveloped, positive-strand RNA virus belonging to the genus *Hepacivirus* and family *Flaviviridae*. HCV is classified into six major genotypes and ~100 subtypes. The viral genome (~9.6 kb) is translated into a single polyprotein of ~3,000 amino acids. A combination of host and viral proteases are involved in polyprotein processing to give at least nine different proteins. This precursor is processed during and after translation to yield the mature structural (core, E1 and E2-p7) and non-structural (NS2, NS3, NS4A, NS4B,

NS5A and NS5B) proteins. The structural proteins of HCV are believed to comprise the core protein (~21 kDa), and two envelope glycoproteins, E1 (~31 kDa) and E2 (~70 kDa).

E1 and E2 proteins are thought to play a role in the HCV lifecycle, both in the assembly of infectious particles and in the initiation of viral infection by binding to its cellular receptor(s). Expression of recombinant E1 and E2 proteins in mammalian cells has shown that they associate into hetero-dimers. Both proteins are glycosylated and lack sialic acid at the termini of their carbohydrate domain in mammalian cells and probably in insect cells. Yet, it is not known whether these proteins form hetero-dimers at the surface of viral particles. In other enveloped viruses, a major role of envelope proteins is to bind to cellular receptor(s) and facilitate virus entry, thereby contributing in determining viral tropism.

E2 protein has also been implicated in the evasion of immune system. The highly variable region (HVR) in the amino-terminus of E2 protein is immunogenic in humans. Antibodies specific for HVR are thought to be neutralizing, suggesting that this region is under an immune selective pressure. Likewise, E2 protein may contribute to HCV resistance to interferon. It may also impair natural killer (NK) cell function. The carboxy-terminal part of E2, p7, is generally cleaved, but only partially in some strains of genotype 1a. Although recent studies suggested that p7 may assist virion assembly and secretion from infected cells, its function remains unknown.

Studies have shown that HCV particles vary in size, between 30 to 60 nm in diameter. In addition, HCV particles display significant heterogeneity in buoyant density on sucrose density-gradient centrifugation, ranging from low (<1.07 g/ml) to high (1.25 g/ml) density. The heterogeneity of particle density has been attributed to the variability in size, nonenveloped nucleocapsid particles, and association with antibodies or β -lipoproteins.

Disease

HCV is the major etiology of non-A, non-B hepatitis that infects 170 millions people worldwide. One of its major characteristics is the high incidence of persistent infection, which may lead to autoimmune disorders and severe liver damage ranging from chronic hepatitis to liver cirrhosis and even hepatocellular carcinoma. Approximately 70-80% of patients develop chronic hepatitis, of which 20-30% progress onto liver cirrhosis.

As hepatocytes represent the primary site of HCV replication in vivo, the HCV genome has also been found in lymphoid cells. Infection of the lymphoid cells has been implicated in extra-hepatic manifestations of HCV infection such as mixed cryoglobulinemia and B-lymphocyte proliferative disorders.

Cellular Receptors for HCV

To date, the cellular receptor(s) for HCV remains controversial. The observations that HCV can infect both hepatic and lymphoid cells suggest that HCV may use different cellular receptors to access different cell types. However, the absence of an in vitro system that supports HCV replication and particle assembly has hampered studies to elucidate the early steps of HCV infection, i.e. virus binding and entry. Association of HCV virions with β -lipoproteins in plasma has raised the possibility that HCV may use LDL receptor (LDL-R) for viral entry. Others have proposed that CD81, a cellular surface protein belonging to the tetraspanin protein superfamily, is the putative receptor for HCV, based on the interaction of CD81 with recombinant truncated E2 protein of HCV 1a.. Nevertheless, several studies have shown that using the truncated E2 protein alone may not accurately reflect interaction of the HCV virion with cells. Both E1 and E2 glycoproteins are known to associate in two types of complexes: (i) heterodimers stabilized by non-covalent bonds, which presumably represents the pre-budding form of the viral envelope, and (ii) high molecular mass disulfide-bonded aggregates representing the misfolded proteins. Indeed, using a pseudotype vesicular stomatitis virus (VSV) expressing either E1 or E2 protein, it has been shown that both proteins are required for efficient infection and fusion into target cells. Furthermore, the HCV virion binds to mononuclear cell lines regardless of their CD81 expression, while recombinant E2 protein bind poorly to that lack of CD81.

Deficiencies

The structure of HCV virions has not yet been elucidated. This is in part due to the difficulties to obtain sufficient amounts of free, purified virion. So far, modeling of HCV ultrastructure is based on data obtained from other members of the Flaviviridae family (dengue and tick-borne encephalitis viruses). Several studies have shown that the genome of HCV is detected in association with other components in the serum: immunoglobulins and β -lipoproteins. Although antibodies recognizing envelope proteins have been detected in the

serum, no demonstration is available on the presence of circulating envelope proteins. A recent report suggests the presence of core containing particles in the serum.

No HCV vaccine is yet available and the current treatment of chronic hepatitis (interferon in combination with ribavirin) is at best only effective in 61% of cases. Efficacy in fact depends in part on the genotype of the infecting HCV strain. The initial steps of HCV infection (binding and entry) that are critical for tissue tropism and hence pathogenesis, is poorly understood. Studies to elucidate this process have been hampered by the lack of robust cell culture systems or convenient small animal models that can support HCV infection. Therefore, there is a need for systems for producing and isolating HCV or HCV virus-like particles.

SUMMARY OF THE INVENTION

The present invention relates to new methods for purifying HCV virus-like particles from insect cells infected with baculoviruses encoding HCV genes. Three methods are disclosed. In one method, glycerol hypertonic/hypotonic shock of infected insect cells results in lysis of cells without alteration of enzymatic activity present in the membranes.

The invention also relates to purified preparations of HCV virus-like particles purified with these methods.

The invention also relates to uses for the HCV virus-like particles. In one embodiment, the HCV virus-like particles are used to make antibodies. In another embodiment, the HCV virus-like particles are used to detect antibodies in a patient that are reactive with HCV. In another embodiment, the HCV virus-like particles are used with cultured cells expressing receptors for HCV, to screen for compounds or substances that interfere with binding of the HCV virus-like particles to the cells and/or interfere with internalization of the HCV virus-like particles by the cells. Methods of treating HCV using the compounds or substances that interfere with binding or internalization, especially those that interfere with HCV binding to asialoglycoprotein receptors, are also part of the invention. In another embodiment, the HCV virus-like particles are used to identify cellular receptors for binding of the virus to cells. In another embodiment, the HCV virus-like particles are used as vaccines or parts of vaccines against HCV.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention may be more readily understood by reference to the following drawings wherein:

Figure 1 is a schematic diagram of recombinant Bac-HCV.1a.S and Bac-HCV.1a.p7 constructs. Two recombinant baculoviruses encoding for the structural proteins HCV of 1a genotype (H77 strain): core, E1 and E2/p7 proteins (Bac-HCV-S) or that of lacking the p7 protein (Bac.HCV-S/p7) were generated.

Figure 2 is a characterization of HCV structural proteins. (A) Profile of HCV-SP after equilibrium sucrose gradient centrifugation. Insect cells were infected with recombinant Bac.HCV-S and were harvested at 3 days post-infection. HCV-S proteins were purified on an equilibrium sucrose gradient centrifugation. One-ml fractions were collected from the top and protein concentration was measured (squares, dotted line). 50 µl of each fraction was tested for E2 reactivity with AP33 mAb by ELISA (diamonds, full line). A similar pattern was observed for HCV-SP/p7 (not shown). (B) Immunoblot analysis of HCV-SP.1a.S with anti-E2 and anti-core antibodies. 50 µl of each fraction was suspended into Laemmli buffer in denaturing conditions and analyzed with 10% SDS-PAGE, then blotted onto nitrocellulose membrane. HCV-SP was tested for E2 and core reactivity by incubating the membrane with AP33 and anti-core mAbs, respectively; antigen-Ab complexes were revealed by incubating the membrane with HRP-coupled anti-mouse antibody, then submitted to chemiluminescence reaction (ECL) and autoradiography. Antibody reactivity against both solubilized E2 and core is indicated with arrows, as well as reactivity against insoluble aggregates (ins. aggr.) on the top of the gel. The last lane (+) is a positive control with recombinant E2 and core proteins expressed in mammalian cells.

Figure 3 is cell binding of HCV-SP and HCV-SP/p7. (A) Binding of light and heavy fractions of HCV-SP to cells. Cells were incubated with HCV-SP derived from strain 1a of HCV; both light (open bars) and heavy (full bars) fractions were tested. Cell-bound HCV-SP was detected by incubating cells with anti-E2 mAb followed by FITC-labeled goat anti-mouse IgG and submitting them to FACS analysis (FACScan). Nonspecific fluorescence was measured by adding primary and secondary antibodies in the absence of HCV-SP to cells. Cytotoxicity of

both light (open triangles) and heavy (crosses) fractions was indirectly evaluated by the shift of cell size and granularity to the bottom left corner. (B) Binding of HCV-SP and HCV-SP/p7 to HepG2 cells. Both light (full symbols) and heavy (open symbols) fractions obtained from Bac.HCV-S (squares) and Bac.HCV-S/p7 (triangles) constructs were tested for cell binding that was measured as above.

Figure 4 is binding of HCV-SP.1a.S to primary human hepatocytes, HepG2 and Molt-4 cells. Cells of various types were incubated with HCV-SP; cell-bound HCV-SP and nonspecific fluorescence were measured. The left panels represent the histogram pattern of HCV-SP binding to target cells. The right panels show the quantified results: a) in percentage of positive cells (diamonds): cells were considered positive when they displayed fluorescence with a value above that of the nonspecific fluorescence threshold; b) in mean fluorescence intensity (MFI; bars): MFI was determined for each cell after subtraction of nonspecific fluorescence value. The results presented were mean value obtained from three independent experiments.

Figure 5 is HCV-SP binding to HepG2 cells which is inhibited by ligands of asialoglycoprotein receptor (ASGP-R). (A) HCV-SP binding to HepG2 cells is calcium-dependent. Cells and HCV-SP were suspended either in binding buffer in the presence of CaCl_2 (full squares) or binding buffer containing 5 mM EGTA in the absence of CaCl_2 (open squares), and binding assay was performed as. (B, C) Effect of ASGP-R ligands on HCV-SP binding in HepG2 cells. In the panel (B), cells were preincubated in binding buffer (with CaCl_2) at 4° C in the presence of various concentrations of asialo-orosomucoid (ASOR), as indicated on the graph; then, binding assay was performed. In the panel (C), cells were preincubated at 4° C with buffer alone (control) or with 1 mg/ml 19S-thyroglobulin (19S-Tg), 0.4 mg/ml asialo-thyroglobulin (asialo-Tg) or anti-ASGP-R peptide polyclonal antibody (1/100), preimmune antibody had no effect (not shown), then with HCV-SP and binding assay was performed.

Figure 6 is internalization of radio-labeled HCV-SP in HepG2 cells. Sf9 insect cells were infected with recombinant Bac.HCV-S baculovirus, then incubated with [^{35}S]-methionine-cysteine mix. HCV-SP was prepared, purified and radio-labeled material (50 $\mu\text{g/ml}$) was incubated with HepG2 cells at 37° C for the indicated time. Cells were harvested, disrupted and submitted to cell fractionation. Four membrane fractions were isolated, each enriched in either

plasma (full circles), microsomal/mitochondrion (full squares), rough endoplasmic reticulum (open triangles) or smooth endoplasmic reticulum (full triangles) membranes. Radioactivity uptake was quantified by liquid scintillation counting.

Figure 7 is co-localization of dye-labeled HCV-SP and ASGP-R GFP-hH1 in the nuclear envelop area. HepG2 cells expressing a fusion protein between GFP and ASGP-R hH1 subunit (GFP-hH1-HepG2 cells) were seeded into sterile glass 8-chamber slides one day before the assay. HCV-SP was dye (CM-DiI)-labeled and purified. GFP-hH1-HepG2 cells were incubated with 10 μ g/ml CM DiI-labeled HCV-SP for 60 min at 37° C; the cells were then rinsed, fixed with 4% paraformaldehyde and the slides were mounted with DAPI/antifade system and kept in the dark at 4° C until they were analyzed by laser scanning confocal microscopy (LSCM) in both green (GFP; top right panel) and red (CM-DiI; top left panel) wavelength channels. Serial horizontal sections (from top to bottom: number 1 to 12) from a single cell obtained in both green and red wavelength channels (top panels) were superposed (bottom left panel); areas displaying co-localization (yellow color = green + red colors) are shown in the bottom right panel: threshold was applied to keep only most significant pixels; darkness increases with intensity of co-localized signals.

Figure 8 is internalization of HCV-SP into GFP-hH1-transfected HepG2 cells. GFP-hH1-HepG2 cells were first incubated with 10 or 20 μ g/ml dye labeled HCV-SP (top panels) or HCV-SP/p7 (bottom panels), or without, as indicated on the figure, in serum-free medium at 4° C for 30 min; this step was followed by further incubation at 37° C for 60 min. The cells were then submitted to LSCM analysis in both green (GFP) and red (CM-DiI) wavelength channels; horizontal sections (6 per cell or group of cells) obtained in both green and red wavelength channels were superposed: areas displaying co-localization appear in yellow color.

Figure 9 is binding of HCV-SP to ASGP-R transfected 3T3-L1 cells. Panel (A), mouse fibroblasts (3T3-L1 cells) were incubated with HCV-SP. Panel (B), 3T3-L1 cells were transfected to co-express two subunits of human liver ASGP-R (hH1 and hH2) and cell lines were established: clone 3T3-22Z co-expressed full length of both hH1 and hH2, whereas clone 3T3-24X co-expressed full length hH1 with a variant of hH2 (hH2') that has a truncated cytoplasmic domain (non-functional variant). Total RNA was extracted from parental 3T3-L1

cells (wt), from clones 3T3-22Z and 3T3-24X, or HepG2 cells and submitted to RT; these cDNAs were then used to amplify by PCR a DNA fragment corresponding to either ASGP-R hH1 or hH2 subunits, as indicated. Panel (C), both 3T3-22Z (squares) and 3T3-24X (triangles) cells, as well as parental 3T3-L1 cells (circles), were challenged with various amounts (2.5-10 $\mu\text{g/ml}$) of either HCV-SP (open symbols) or HCV-SP/p7⁻ (full symbols) and incubated for 2 hrs at 4° C. Cell-bound HCV-S protein was detected by flow cytometry. Histograms of the binding of either HCV-SP (top panels, 4° C) or HCV-SP/p7⁻ (middle, 4° C, and bottom, 37° C, panels) to 3T3-22Z (right panels) and 3T3-24X (left panels) cells are presented in panel (D).

Figure 10 is internalization of labeled HCV-SP into ASGP-R transfected 3T3-L1 cells. Panel (A), ASGPR hH1/hH2-dual-transfected 3T3-L1 cells (clone 3T3-22Z = 22Z + 19 or clone 3T3-24X = 24X + 19) or wild-type 3T3-L1 cells (wt) were incubated in the presence of 10 μ g/ml labeled HCV-SP or HCV-SP/p7 for 30 min at 37° C. The cells were submitted to LSCM analysis in the red (CM-DiI) wavelength channel. Sections of two distinct cells are shown for each condition. Panel (B), 3T3-22Z cells were incubated with 10 μ g/ml CM-DiI-labeled HCV-SP for 30 min at 37° C; 15 sections were obtained after LSCM analysis of a single positive cell and are shown from the top (upper left picture) to the bottom (lower right picture).

Figure 11 is characterization of HCV-LPs 1a. (A) HCV-LPs 1a were harvested on day 3 post-infection and purified. Eleven fractions (1 ml) were collected from the top and tested for E2 reactivity by ELISA. (B) Western blot analysis of HCV-LPs. The similar fractions collected from (A) were run on SDS-PAGE, followed by Western blot analysis with anti-E2 (ALP98), anti-E1 (A4) and anti-core (C1) mAbs. (C) Cryoelectron micrograph of HCV-LP 1a. Bar, 200 nm.

Figure 12 is HCV-LPs binding to human hepatic and T cells. Binding of HCV-LPs to human hepatic (primary human hepatocytes, HepG2, HuH7, NKNT-3) and T (Molt-4) cells was detected by anti-E2 mAb followed by FITC-labeled goat anti-mouse IgG (indirect method). *x* axis, the mean fluorescence intensity (MFI); *y* axis represents the number of cells. HCV-LPs did not bind to Aro, a human thyroid cell line.

Figure 13 is characteristics of HCV-LP binding to cells. (A & B) Dose-dependent binding. Binding of HCV-LPs to PHH, HepG2, NKNT-3 and Molt-4 cells were analyzed.

Nonspecific fluorescence was measured by adding primary and secondary antibodies to cells in the absence of HCV-LPs. The MFI was determined after subtracting nonspecific fluorescence value. Results presented are representative of three independent experiments. (C) Calcium-dependent binding. NKNT-3 cells and HCV-LPs were resuspended in 10 mM Tris- HCl, 150 mM NaCl buffer containing 5 mM EGTA, and the binding assay was performed. (D &E) Scatchard plot analysis of HCV-LPs binding. SYTO-labeled HCV-LPs (1-200 μ g/ml) were incubated with cells for 1 h at 4°C. After washing, cell-bound HCV-LPs were analyzed by flow cytometry. Bound (B) and free (F) HCV-LPs for each concentration was determined based on the MFI of 100 μ g/ml HCV-LPs in the absence of cells regarded as total input (T).

Figure 14 is inhibition of HCV-LPs binding to cells by anti-E1 and -E2 antibodies. SYTO-labeled HCV-LPs were pre-incubated with 20-100 μ g/ml of anti-E2 (AP33, ALP98), anti-E1 (A4), or isotype control IgG for 2 h at 4°C. The HCV-LPs-antibody mixtures were then incubated with Molt-4 cells for 1 h. Cell-bound HCV-LPs were analyzed. (A) Flow cytometry histogram of HCV-LPs binding in the presence (20 μ g/ml) (open graph) and absence (black filled graph) of antibodies. Background binding is shown as the gray graph. (B) Dose response inhibition of HCV-LPs binding by the respective antibodies.

Figure 15 is effect of CD81 on HCV-LP binding to cells. (A) Effect of human LEL-CD81 on HCV-LP binding. SYTO-labeled HCV-LPs were pre-incubated with increasing amounts of soluble human LEL-CD81 for 2 h at 4°C prior to addition to Molt-4, NKNT-3 or HuH7 cells. The binding assay was performed. The top panel shows the flow histograms and the bottom the MFIs. (B) Effect of anti-CD81 on HCV-LP binding. Molt-4 and HuH7 cells were pre-incubated with mouse anti-human CD81 IgG (20 μ g/ml) for 2 h at 4°C, then SYTO-labeled HCV-LPs were added and further incubated for 1 h at 4°C. Cell-bound HCV-LPs were analyzed.

Figure 16 is effect of VLDL, LDL and HDL on HCV-LP binding to Molt-4 cells. Cell-bound HCV-LPs were analyzed by flow cytometry using indirect method (A & B) or direct method (C). (A) Increasing concentrations of HCV-LPs with or without LDL (0.5 mg/ml) were added simultaneously to cells. (B) Alternatively, HCV-LPs were pre-incubated with LDL for 2 h

at 4°C before added to cells. (C) SYTO-labeled HCV-LPs were incubated with cells for 1 h at 4°C and cell-bound HCV-LPs were analyzed as described in M&M (open bar). Cells were pre-incubated with VLDL, LDL, HDL (0.5 mg/ml), or anti-human LDL-R IgG (20 µg/ml), for 2 h at 4°C, before addition of SYTO-labeled HCV-LPs (striped bar). Alternatively, SYTO-labeled HCV-LPs were pre-incubated with VLDL, LDL, or HDL at 4°C, before added to cells (closed bar).

Figure 17 is confocal microscopy analysis of labeled-HCV-LPs internalization by cells. HuH 7 cells were incubated with CM-DiI labeled HCV-LPs at 4°C (A) and then at 37°C (B). As negative control, cells were incubated with CM-DiI labeled control Bac-GUS preparation at 37°C (C). NKNT-3 cells were incubated with SYTO-labeled HCV-LPs at 4°C (D) and then at 37°C for 30 min (E). As negative control, cells were incubated with SYTO-labeled Bac-GUS at 37°C for 30 min (F). NKNT-3 cells were incubated with SYTO-labeled HCV-LPs for 15 min at 37°C (G). Alternatively, cells were incubated with SYTO-labeled HCV-LPs that had been pre-incubated with anti-E1/-E2 antibodies for 2 h (H). On each panel, six images represent the top to the bottom of cells (left to right) are shown.

Figure 18 is a profile of new HCV-LP following equilibrium sucrose gradient centrifugation. (A) 10^8 cells were grown in SF900 II medium (GIBCO BRL) and infected with Bac.HCV.1a.S at a multiplicity of infection (MOI) of 1 or 10 for 1 hr at 27°C. Without removing the inoculum, fresh medium containing 0.5% fetal bovine serum and antibiotics/antifungic was added to reach a total volume of 30 ml. Cells were grown at 27° C (125 rpm) and harvested at either 2, 3, or 4 days post-infection. All purification steps were carried out on ice. The pellet was resuspended in TNC buffer, and applied onto a 20-60% sucrose gradient and centrifuged at 100,000 x g for 16 hours. Ten 500 µl-fractions were collected from the top of the tube. Fractions containing HCV-LP were stored at -70 C. Protein concentration was determined using Coomassie Plus protein assay reagent with BSA as the protein standard. (B) Fractions collected from (A) were analyzed by SDS-PAGE followed by Western Blot using specific anti-E2 (ALP98), anti-E1 (A4) and anti-core (C1) monoclonal antibodies. The figure shows fractions 3-9 of HCV-LP purified from insect cells 3 days post-infection with MOI 10.

Figure 19 shows histograms of HCV-LP binding to human hepatic cells NKNT-3 (before and after transduction with AdCANCRe, HuH7, and kidney (293) cells. Human hepatic cells (HuH7) and kidney cells (293) were obtained from American Type Culture Collection. An immortalized human hepatocytes (NKNT-3) and a replication-deficient recombinant adenovirus (Ad) that express the Cre recombinase tagged with a nuclear localization signal (AdCANCRe) was used. Differentiation of NKNT-3 cells to mimic normal primary hepatocytes was achieved by transduction with AdCANCRe followed by selection with G418 (Ad-NKNT-3). Cells were grown in Chee's Modified MEM containing 5% fetal bovine serum and were analyzed for HCV-LP binding at 3 days post-transduction. HCV-LP was directly labeled with SYTO-12 (nucleic acid dye) according to the manufacturer's protocol. Briefly, HCV-LP were incubated with 5 µM of SYTO-12 in TNC buffer at 4°C for 15 min and re-purified through a 30% sucrose cushion to remove free dye. 2×10^5 cells were incubated with 2.5 µg of SYTO 12-labeled HCV-LP in 50 µl TNC buffer containing 1% BSA and a cocktail of EDTA-free protease inhibitors, for 1 hr at 4° C. Cells were washed once with PBS, detached with 0.25 mM EDTA (in PBS) for 10 min at 37°C, and resuspended in binding buffer. After washing, cell-bound HCV-LP were analyzed by

flow cytometry. For each cell type, histogram shown is cells in the absence of HCV-LP (gray graph) and after incubation with HCV-LP (black graph).

Figure 20 shows the effect of anti-E2, anti-E1 and anti-core antibodies on HCV-LP binding to Ad-NKNT-3 cells. SYTO 12-labeled HCV-LP were pre-incubated with 20 µg/ml of anti-E2 (ALP98), anti-E1 (A4), or anti-C mAbs for 2 h at 4°C and were then incubated with Ad-NKNT-3 cells for 1 h (open graph). As control, cells were incubated with HCV-LP in the absence of antibodies (closed graph). After washing, cell-bound HCV-LP were analyzed.

Figure 21 shows the effect of lipoproteins on HCV-LP binding to NKNT-3 and Ad-NKNT-3 cells. Cells were transduced with recombinant AdCANCRe, and HCV-LP binding was performed at 3 days post-transduction. 2×10^5 cells were incubated with 1.5 or 2.5 µg of SYTO 12-labeled HCV-LP (closed bar) for 1 hr at 4°C, and analyzed by flow cytometry. (A, B) NKNT-3 or Ad-NKNT-3 cells were pre-incubated with apolipoprotein E4 for 2 hr at 4°C before adding HCV-LP and incubating for another 1 hr (striped bar). (C, D) Cells were pre-incubated with 0.5 mg/ml of LDL (hatched or striped bar) or without (closed bar), as a control, before adding dye-labeled HCV-LP. Alternatively, HCV-LP were pre-incubated with LDL before adding to cells (open bar). (E, F) Cells were pre-incubated with 0.5 mg/ml of HDL before adding dye-labeled HCV-LP (hatched bar); as a control, cells were incubated with HCV-LP in the absence of LDL (closed bar). Alternatively, HCV-LP were pre-incubated with HDL before adding to cells (open bar).

Figure 22 shows the effect of AGSP-R ligands on HCV-LP binding to NKNT-3 and Ad-NKNT-3 cells. (A) Cells were pre-incubated with rabbit anti-ASGPR antibody for 2 hr at 4°C before added with SYTO 12-labeled HCV-LP (striped bar). As control, cells were incubated with HCV-LP in the absence of anti-ASGP-R antibody (closed bar). (B) Cells were pre-incubated with 0.5 mg/ml of Tg 19S for 2 hr at 4°C before SYTO 12-labeled HCV-LP was added (striped bar). Alternatively, HCV-LP were pre-incubated with Tg 19S for 2 hr at 4°C before added to cells (open bar).

DETAILED DESCRIPTION OF THE INVENTION

Because of the lack of systems to replicate HCV in cultured cell systems and, therefore, the inability to obtain the purified virus in quantity, virologists have attempted to express HCV genes in various expression systems with the idea that expressed HCV proteins would assemble into virions or virion-like structures. It is well known that expression of recombinant virus structural proteins in insect cells leads to the spontaneous formation of pseudo-viral particles, so called viral- or virus-like particles.

In 1998, Baumert et al. reported that expression of recombinant structural proteins of HCV in insect cells led to the formation of virus-like particles, so-called hepatitis C virus-like particles (HCV-LP). The structural proteins of HCV derived from 1b genotype were cloned into baculovirus allowing their expression under control of the polyhedrin promoter. These investigators also described a method of purifying the HCV-LP from the infected insect cells. Insect cells were infected with an inoculum of recombinant baculovirus at a multiplicity of infection per cell in general of 1. Four days after infection, insect cells were harvested and lysed by sonication and homogenized in 50 mM Tris-HCl, pH 7.4, containing 50 mM NaCl, 0.5 mM EDTA and 0.1% NP40. Cell lysates containing HCV-LP were centrifuged through a 30% sucrose cushion at 150,000 x g for 6 h. The pellet was then analyzed on a 20-60% sucrose gradient at 150,000 x g for 22 h and 10 fractions were collected.

The Baumert et al. method results in a low yield of HCV-LP. In addition, the HCV-LP resulting from this method is heterogeneous and contains contaminating baculovirus. This is a disadvantage, especially if the particles are to be used to immunize individuals, as the impurities present in the preparation might cause adverse immune reactions. The HCV-LP preparations that are obtained showed poor binding to target cells and significant death of those cells. Therefore, although HCV-LP particles are produced by cells infected with baculoviruses encoding HCV genes, purification of the particles from the infected cells has not yielded pure HCV-LP and the quantities of HCV-LP obtained is not sufficient for significant further biological studies.

In the first method for virus-like particle purification from baculovirus infected cells (Example 2), cells are lysed with digitonin in the presence of protease inhibitors. Preferably, the concentration of digitonin used is 0.25%. Insoluble debris are removed by centrifugation and the supernatant is precipitated with a solution of polyethylene glycol (PEG). Various concentrations of PEG can be used, at various pH and in various buffers, depending on the time and temperature of treatment. Preferably, PEG 8000 is used at a concentration of 10%. The PEG precipitate is layered onto a sucrose gradient and centrifugation is performed. After a suitable time of centrifugation, fractions are collected from the sucrose gradient and tested for the presence of virus-like particles. This testing can be done in a variety of ways. One way is analysis of the proteins within the collected fractions by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). This separation technique may be used as a prelude to Western blotting, where HCV proteins are detected using one or more antibodies specific for the proteins. Such methods are well known in the art.

In the second method for virus-like particle purification (Example 11), baculovirus-infected cells are again lysed with digitonin. Insoluble debris are removed by centrifugation and the supernatant is centrifuged over a 30% sucrose cushion. The pellet is resuspended and layered onto a gradient and ultracentrifugation is performed. The gradient can be a sucrose gradient. Alternatively, the gradient can be of various types known in the art. For example, the gradient can comprise cesium chloride or other iodinated compounds, nycodenz or iodoxanol for example. After a suitable time of centrifugation, fractions are collected from the gradient and tested for the presence of virus-like particles, as described above.

The third method for purification of virus-like particles (Example 18) allows the release of viral particles from infected cells before a low concentration of detergent is added. The method uses suspension of cells in a hypertonic buffer (e.g., glycerol), then in a hypotonic buffer (e.g., Hepes). It is also possible to use other components or steps to achieve successive treatment in a hypertonic buffer and a hypotonic buffer. For example, sucrose or hypertonic saline solution can be followed by hypotonic shock. The detergent addition step then follows.

The virus-like particles obtained from the methods of purification described above are characterized. Such particles contain one or more, preferably all, of the HCV proteins expressed in the baculovirus-infected insect cells. Such particles also contain lipid. Such particles may or may not contain nucleic acid. Nucleic acid contained in the particles is preferably RNA.

There are a variety of methods well known in the art of virology for characterizing virus particles. SDS-PAGE with or without Western blotting has already been described. Other immunological methods, ELISA for example, can also be used to detect and analyze proteins present within or associated with the virus-like particles. Electron microscopy can be used to visualize and even to measure the size of the particles. Cryoelectron microscopy can be used. Centrifugation can be used to determine buoyant density of the particles. Other methods can be used to detect and analyze a genome that may be present within the particles.

Other assays may be used to ascertain various functions of the particles. For example, assays to determine whether the virus-like particles bind to host or target cells can be used. The same or other assays can be used to determine whether the particles enter host or target cells. Some such assays are described in various Examples of this application.

In addition there are many techniques and methods that exist in the art of virology that can be used to detect and measure various aspects of viruses or virus particles or their functioning or interaction with cells. Such methods are well known in the art and can be found in numerous textbooks or laboratory manuals of virology. Such methods can be used to analyze and test the virus-like particles of the present invention and their functioning.

Briefly, the characteristics of the HCV virus-like particles obtained by the three different methods of purification described above are as follows. The particles resulting from the first purification method described above are HCV structural proteins associated under the form of lipid vesicles or micelles. The particles resulting from the second purification method described above are irregular particles containing E1-E2 envelope proteins representing three subpopulations of particles that are more apparent when the third purification method is used. The particles resulting from the third purification method described above are a homogeneous preparation of particles approximately 50 nm in size with an apparent structure resembling other known viruses of the family *Flaviviridae*. This latter method of purification preserves the structure of the virus-like particles during the purification process. Other characteristics of the HCV virus-like particles obtained from the three different methods of purification are described in the Examples of this application.

Assays to detect HCV in a sample or to determine if an individual is or has been exposed or infected with the virus can be of a variety of types. One type of assay depends on detecting antibodies in a subject that are cross reactive with the HCV virus-like particles. Many such assays are well known in the art. For example, such assays include competitive binding assays, direct and indirect sandwich-type immunoassays, agglutination assays and precipitation assays.

Cell-free assays can be used to measure the binding of human antibodies in serum to HCV virus-like particles. For example, the particles can be attached to a solid support such as a plate or sheet-like material and binding of anti-HCV antibodies to the immobilized HCV-like particles can be detected by using a labeled anti-human immunoglobulin to visualize the bound anti-HCV antibodies attached to the HCV-like particles on the support. Similarly, the virus-like particles can be attached to inert particles such as latex beads which can be used to detect human anti-HCV antibodies by detecting agglutination or capture of the particles at a discrete position.

17

The serum-contacted particles are then contacted with the cultured cells and it is determined whether the virus-like particles are able to bind to the cells. If the patient serum contained antibodies specific for HCV, the antibodies bind to or inactivate the HCV virus-like particles. In such case, no binding of the HCV virus-like particles to the cells is detected. In the control study, where the HCV virus-like particles were not contacted with patient serum, the particles bind to the cells.

In another embodiment of this assay, a sample from a patient suspected of containing HCV is contacted with the cultured cells to which HCV virus-like particles are capable of binding. Subsequently, HCV virus-like particles are contacted with the cells and it is determined whether the particles bind to the cells. In the case where the patient sample contains HCV, the HCV binds to the cells and inhibits binding of the HCV virus-like particles.

Binding of the HCV virus-like particles to the cells in assays as described above can be detected and quantified in a variety of ways. In one technique, the particles may be labeled using radioactive or nonradioactive labels. The label may be directly or indirectly coupled to the particles using methods well known in the art. For example, HCV-like particles may be radioactively labeled with ^3H , ^{125}I , ^{35}S , ^{14}C or ^{32}P using standard in vivo or in vitro labeling methods and the binding of HCV-like particles to cells may be detected using autoradiography or scintillation counting. The particles may also be labeled with labels that are non-radioactive. One such non-radioactive label attaches to the lipids of the virus envelope. The CellTracker dyes from Molecular Probes are of this type. Another type of dye binds to the nucleic acid of the particle. One dye of this type are certain of the SYTO dyes, also available commercially from Molecular Probes.

Binding of the HCV virus-like particles to cells can also be detected using, for example, antibodies reactive with the particles, the antibodies being labeled with fluorophores, chemiluminescent agents, enzymes, colloidal gold and the like.

It should also be recognized that the HCV virus-like particles can be used as an antigen to produce antibodies reactive with HCV. Such antibodies can be used in a variety of ways. One such use is to detect HCV in a sample from a patient in a diagnostic assay, many of which are known in the art. The anti-HCV antibodies can be made by a variety of methods that are well known in the art. In one such method, the HCV virus-like particles are injected into an animal, a rabbit, mouse, rat, rabbit, goat, sheep or horse, for example, to cause the animal to have a

humoral immune response. In such animals, the serum contains antibodies specific for HCV. Antibodies can be used to detect HCV in patient samples.

In another method, HCV virus-like particles are used to make monoclonal antibodies, using methods well known in the art. Monoclonal antibodies that bind to HCV-particles can readily be produced by fusing lymphatic cells isolated from an immunized animal using well known techniques. Polyclonal or monoclonal antibodies that bind to HCV-particles may be bound to a variety of solid supports such as polysaccharide polymers, filter paper, nitrocellulose membranes or beads made of polyethylene, polystyrene, polypropylene or other suitable plastics.

Assays to screen for compounds or substances that interfere or prevent binding of HCV and HCV virus-like particles to cells can be of a variety of types. The HCV virus-like particles can be used to assay for proteins, antibodies or other compounds capable of inhibiting interaction between HCV and mammalian cells. For example, compounds that interfere with the ability of HCV to effectively contact human cells can be detected by measuring the ability of labeled HCV virus-like particles to bind to human cells, in vivo or in vitro, in the presence of the compound compared to control conditions where the compound is not present. Cell lines used in such assays have receptors for binding of HCV. Exemplary cell lines for detecting such interference with HCV-like particles include Capan-1, Hep 3B, Hep G2, SK-HEP-1, Chang liver, Daudi, MOLT-4 and WRL 68, all available from the American Type Culture Collection (Rockville, Md.), and HuH7 cells, available from many research laboratories. Other such cell lines are primary human hepatocytes, HepG2 cells and Molt-4 cells.

Cells that do not have receptors for HCV can also be used if the cells are manipulated in such a way that the cells express the receptors. Such cells that do not have receptors are 3T3-L1 cells, for example. One method for manipulating cells that do not express receptors is to transfect or otherwise introduce into the cells and express therein a nucleotide or nucleotide sequences that encode such receptors. Such nucleotide sequences are, for example, cDNAs from human liver encoding the hH1 and hH2 of the asialoglycoprotein receptor (ASGP-R).

Purified HCV virus-like particles are contacted with the cells and it is determined if the particles bind to the cells. Binding can be determined in a variety of ways. One way to determine binding is to label the HCV virus-like particles. The particles can be radioactively labeled or can be non-radioactively. In the case of radioactively labeled virus, binding of the virus to cells can be detected by autoradiography or scintillation counting of the cells. In the

case of non-radioactively labeled virus, for example in the case where the virus has been labeled with a fluorochrome, fluorescence imaging of the cells will detect the attached virus. Alternatively, the fluorochrome-labeled virus can be detected after flow cytometry analysis of the cells. Binding of the HCV virus-like particles to the cells can also be detected in the case that the virus is not labeled. In this case, virus bound to cells can be detected by contacting the cells and attached virus with an antibody reactive with the virus. If the antibody is labeled with a fluorochrome or reacted with a second antibody that is labeled with a fluorochrome, attached virus can be detected after imaging or flow cytometry analysis of the cells.

Using such a cell binding assay, compounds or substances suspected of interfering with the binding of HCV virus-like particles and HCV to cells, is detected by first contacting the substance with either or both of the cells or the HCV virus-like particles, then contacting the cells with the particles and assaying for binding of the particles to the cells. Compounds or substances that interfere with particle binding will cause a reduction in the measurement of particles bound to the cells as compared to controls where no compound or substance was added before the cells and particles were contacted with one another.

Another type of assay system that can be used takes advantage of the finding that HCV, when replicating in a hepatic cell, induces expression of MHC class I molecules on the cell surface. This observation has been used to create cell lines that are readily used as assay targets for HCV infection. To do this, a nucleotide sequence encoding a receptor for HCV is introduced into cultured cells. For example, nucleotide sequences encoding subunits of ASGP-R are transfected into cells. The cells can be cells that have no receptors (e.g., fibroblasts) or can be cells that express receptors (e.g., HepG2 cells). In the latter instance, the level of receptors on the cell surface is enhanced. Into the same cells is also introduced a MHC class I transcriptional promoter regulating expression of a marker gene, luciferase for example. Other promoters that can be used are TAP, LMP2, MHC class II and others. These cells, expressing receptors for HCV and encoding a marker gene regulated by an HCV-inducible transcriptional promoter are then used as target cells. Such cells are called indicator cells. For example, HCV or HCV virus-like particles that contact the viral receptors on the surface of the indicator cells will cause induction of transcription of the marker gene, luciferase in this case. Induction of the marker gene is conveniently detected. Such indicator cells can be used to assay for HCV in fluid samples from a patient. Such cells can also be used to assay for antibodies reactive with HCV in

fluid samples of a patient. For example, HCV virus-like particles are contacted with the fluid sample. Antibodies therein that are reactive with HCV, bind to the HCV virus-like particles and inactivate them. Subsequent contact of the fluid-treated HCV virus-like particles with the indicator cells do not cause induction of expression of the marker gene to the same extent as contact with the cells of HCV virus-like particles that have not been contacted by patient fluid not containing HCV-reactive antibodies.

Similarly, the indicator cells, along with the HCV virus-like particles, can be used to screen various substances and compounds for the ability to inhibit binding of HCV to a cell and/or to inhibit internalization of HCV into a cell. To do this, the indicator cells and/or HCV virus-like particles are contacted with a desired substance or compound. Subsequently, the HCV virus-like particles are contacted with the indicator cells and the level of induction of the marker gene is measured. Substances or compounds that inhibit HCV binding to the cells and/or internalization of HCV by the cells, will cause a reduction in the expression level of the marker gene of the indicator cells as compared to a similar control experiment where no substance or compound was used.

Similarly, antibodies that interfere with HCV infection of human cells can be detected and their ability to block infection can be measured by assaying the level of interaction between HCV virus-like particles and human cells (such as hepatocytes and Chang liver or WRL 68 cells) in the presence of the antibodies compared to the level of interaction achieved when the antibodies are absent.

Another type of assay can be used to measure internalization of virus by cells. In such an assay, virus is detected within cells. One method of doing this is by labeling HCV virus-like particles. The particles may be labeled by any of the methods described above. The labeled particles are contacted with cells and, at some later time, the cells are examined to determine if labeled virus or virus components can be detected within the cell. For example, in the case where radioactively labeled HCV virus-like particles are used, autoradiography of intact cells can be used to detect internalization. Another method is fractionation of various cell components or compartments using cell biological and/or biochemical techniques that are well known in the art. After the cell components are fractionated, scintillation counting is used to detect the radioactive label and determine if the virus has been internalized by the cell and where within the cell the HCV virus-like particles are located. In the case where HCV virus-like particles are not

radioactively labeled, but, for example, are labeled with some type of fluorochrome as described earlier, cells can be fixed and then examined using methods such as confocal microscopy and flow cytometry.

The invention also encompasses methods of treating HCV infection in a patient using compounds or substances identified through use of the above assays, that inhibit binding of HCV to cells and/or inhibit internalization of HCV into target cells. Some such compounds or substances bind to ASGP-R or prevent binding of HCV to ASGP-R. Some such substances that have been identified include Asialo-orosomucoid, thyroglobulin, asialo-thyroglobulin and antibodies reactive against peptides in the ASGP-R, such antibodies are preferably humanized antibodies. One specific antibody reactive against ASGP-R is a polyclonal antibody specific for a peptide of the CRD of hH1 subunit of the ASGP-R. Such compounds and substances can be used therapeutically to treat individuals infected with HCV or even prophylactically to prevent infection of individuals by HCV. The compounds and substances used in these methods are prepared into pharmaceutically acceptable compositions and easily administered to individuals at dosages that are therapeutically effective.

Compositions Containing HCV Virus-Like Particles for Induction of an Immune Response

Vaccination against and treatment of HCV infection may be accomplished using pharmaceutical compositions, including HCV virus-like particles. Suitable formulations for delivery of HCV-like particles are found in Remington's Pharmaceutical Sciences, 17th ed. (Mack Publishing Co., Philadelphia, Pa., 1985). These pharmaceutical compositions are suitable for use in a variety of drug delivery systems (Langer, Science 249:1527-1533, 1990).

HCV virus-like particles in compositions are suitable for single administration or in a series of inoculations (e.g., an initial immunization followed by subsequent inoculations to boost the anti-HCV immune response). The pharmaceutical compositions are intended for parenteral, topical or oral administration. Parenteral administration is preferably by intravenous, subcutaneous, intradermal, intraperitoneal or intramuscular administration. Parenteral administration may be preferentially directed to the patient's liver such as by catheterization to hepatic arteries or into a bile duct. For parenteral administration, the compositions can include HCV-like particles suspended in a suitable sterile carrier such as water, aqueous buffer, 0.4%

Solid compositions including HCV virus-like particles in conventional nontoxic solid carriers such as, for example, glucose, sucrose mannitol, sorbitol, lactose, starch, magnesium stearate, cellulose or cellulose derivatives, sodium carbonate and magnesium carbonate. For oral administration of solid compositions, the HCV-like particles preferably comprise 10% to 95%, and more preferably 25% to 75% of the composition.

HCV virus-like particles can also be administered in an aerosol such as for pulmonary and/or intranasal delivery. The HCV virus-like particles are preferably formulated with a nontoxic surfactant (e.g., esters or partial esters of C6 to C22 fatty acids or natural glycerides) and a propellant. Additional carriers such as lecithin may be included to facilitate intranasal delivery.

HCV virus-like particles can be used prophylactically as a vaccine to prevent HCV infection. A vaccine containing HCV virus-like particles contains an immunogenically effective amount of the particles in a pharmaceutically acceptable carrier such as those described above. The vaccine may further include carriers known in the art such as, for example, thyroglobulin, albumin, tetanus toxoid, polyamino acids such as polymers of D-lysine and D-glutamate, inactivated influenza virus and hepatitis B recombinant protein(s). The vaccine may also include any well known adjuvant such as incomplete Freund's adjuvant, alum, aluminum phosphate and aluminum hydroxide. Double-stranded nucleotide or polynucleotides can also be used as adjuvants. When double-stranded polynucleotides are used as antigens, the vaccine preparation is preferably administered to the individual by intramuscular injection. The immune response generated to the HCV virus-like particles may include generation of anti-HCV antibodies and/or generation of a cellular immune response (e.g., activation of cytotoxic T lymphocytes or CTL) against cells that present peptides derived from HCV.

Vaccine compositions containing HCV virus-like particles are administered to a patient to elicit protective immune response against HCV, which is defined as an immune response that prevents infection or inhibits the spread of infection from cell to cell after an initial exposure to

the virus. An amount of HCV virus-like particles sufficient to elicit a protective immune response is defined as an immunogenically effective dose. An immunogenically effective dose will vary depending on the composition of the vaccine (e.g., containing adjuvant or not), the manner of administration, the weight and general health of the patient and the judgment of the prescribing health care provider. For initial vaccination, the general range of HCV-like particles in the administered vaccine is about 100 μ g to about 1 gm per 70 kg patient; subsequent inoculations to boost the immune response include HCV virus-like particles in the range of 100 μ g to about 1 gm per 70 kg patient. A single or multiple boosting immunizations are administered over a period of about two weeks to about six months from the initial vaccination. The prescribing health care provider may determine the number and timing of booster immunizations based on well known immunization protocols and the individual patient's response to the immunizations (e.g., as monitored by assaying for anti-HCV antibodies or to avoid hyperimmune responses).

For treatment of a patient infected with HCV, the amount of HCV virus-like particles to be delivered will vary with the method of delivery, the number of administrations and the state of the person receiving the composition (e.g., age, weight, severity of HCV infection, active or chronic status of HCV infection and general state of health). Before therapeutic administration, the patient will already have been diagnosed as HCV-infected and may or may not be symptomatic. A therapeutically effective dose of HCV virus-like particles is defined as the amount of HCV-like particles needed to inhibit spread of HCV (e.g., to limit a chronic infection) and thus partially cure or arrest symptoms or prevent further deterioration of liver tissue. Generally, a therapeutically effective dose of HCV virus-like particles will be in the range of about 1 mg to about 10 gm per day, preferably about 50 mg to about 5 gm per day, and most preferably about 100 mg to 1 gm per day for a 70 kg patient.

In one embodiment, HCV virus-like particles are used to immunize the human or animal generally using a procedure where about 10 to 100 μ g, preferably about 50 μ g of the particles are initially administered to the animal to induce a primary immune response followed by one to about five booster injections of about 10 to 100 μ g of HCV virus-like particles over a period of about two weeks to twelve months. Depending on the size of the animal to which the particles are administered, the dosage may vary, as will be readily determined by those skilled in the art. The timing and dosage of the booster injections in particular are determined based on the

immune response detected in the animal, using methods well known to those skilled in the art. The virus-like particles are preferably administered subcutaneously as a suspension that includes an adjuvant such as Freund's complete or incomplete adjuvant, although a wide variety of available adjuvants are also suitable.

Another type of pharmaceutical composition that can be administered for the purpose of stimulating a protective immune response against HCV is a composition comprising HCV virus-like particles and cells, preferably cells that are antigen presenting cells. In one embodiment, dendritic cells are isolated from an individual and contacted with HCV virus-like particles. The dendritic cells internalize the HCV virus-like particles. The dendritic cells that have been contacted with HCV virus-like particles are then administered to an individual as part of a pharmaceutical composition, for the purpose of stimulating an immune response in the individual that is protective or therapeutic for HCV infection. Although dendritic cells can be used in this procedure, other types of antigen presenting cells can be used. It is also possible to take cells that are not antigen presenting cells, and express within those cells, increased levels of MHC class I and/or MHC class II molecules. Such cells are also made to express, on the cell surface, molecules to which an immune response is desired, HCV proteins for example. Such cells, expressing both MHC and the desired antigen, are used as a component of the pharmaceutical composition comprising the vaccine. This procedure is advantageous in that the previously described immunization procedures, in which HCV virus-like particles alone (no cells) comprise the vaccine, is that such procedures usually induce immune responses to dominant antigens, which are not always the protective antigens important for host defense.

In another embodiment, immunization is performed using a pharmaceutical composition made as follows: monocytes are isolated from an individual, transfected with double-stranded DNA and one or more genes encoding HCV proteins. The cells are then treated with mitomycin C, or other treatment to kill the cells, and administered back into the individual, preferably by intramuscular or intraperitoneal injection.

In another embodiment, immunization is performed using a pharmaceutical composition made as follows: monocytes are isolated from an individual, transfected with a polynucleotide sequence encoding ASGP-R. These cells are then exposed to HCV proteins, which bind to and are internalized by the cells. These cells are then treated with mitomycin C and administered back into the individual as above.

In any of the embodiments where the pharmaceutical composition used for the vaccine comprises cells and HCV proteins, the cells can be contacted with one or more cytokines before administration into the individual for the purpose of providing cells that are better able to stimulate an immune response when administered to the individual.

In addition, one or more of the above compositions may be combined to provide an effective pharmaceutical composition to be used for immunization against HCV.

EXAMPLES

The invention may be better understood by reference to the following examples, which serve to illustrate but not to limit the present invention.

Example 1. Baculoviruses Expressing HCV Proteins

Two recombinant baculoviruses expressing the structural proteins of HCV derived from 1a genotype (H77 strain) were generated (Figure 1). These two constructs express core, E1 and E2-p7 or core, E1 and E2 without p7.

A plasmid containing an infectious HCV clone of the 1a genotype H77 strain, p90/HCV.FL-long pU (gift of M.E. Major & S.M. Feinstone; FDA; Bethesda, MD), was used as a template to generate two recombinant baculoviruses coding for the structural HCV proteins: core, E1 and either E2/p7⁺ (Bac.HCV-S) or E2/p7 (Bac.HCV-S/p7). The Bac.HCV.S has an additional 63 nt of the amino terminal part of NS2. This plasmid was digested with *Stu* I and *Tth*111 I, releasing a DNA fragment (nt 278-2831) corresponding to core, E1 and E2/p7⁺ proteins, which was subcloned between the *Stu* I-*Xba* I sites of a pFastBac plasmid, allowing its expression under the control of a polyhedrin promoter (pFB90S). A second DNA fragment (nt 1814-2579) was generated from p90/HCV.FL-long pU; PCR was performed with *Pfu* DNA polymerase and the two following primers 5'-AAG ACC TTG TGG CAT TGT GC-3' (sense) and 5'-TCG AAA GCT TAC GCC TCC GCT TGG GAT ATG AGT-3' (anti-sense); for construct purpose, a *Hind* III site (underlined) was introduced in this amplimer. The 775-bp PCR product was subcloned into the *Sma* I site (blunt-end) of pUC19 vector (pUC775). pUC775 and pFB90S plasmids were digested with *Asc* I and *Hind* III, respectively, to obtain a 671-bp DNA fragment (nt 1909-2579) and to remove a fragment (nt 1909-2831) of pFB90S. The 671-bp fragment was then ligated with the truncated plasmid (pFB90S/p7) that encodes for a E2/p7

protein. The schematic diagram of the cloning procedures is shown in Figure 1. The nucleotide sequences of the recombinant baculoviruses were verified by restriction enzyme analysis and DNA sequencing.

Plasmids pFB90S and pFB90S/p7 were used to generate recombinant baculoviruses, Bac.HCV-S and Bac.HCV-S/p7, respectively, using BAC-to-BAC Baculovirus Expression System (Gibco-BRL/Life Technologies, Gaithersburg, MD) according to the manufacturer's protocols. Virus titer was determined by BacPAK Baculovirus Rapid titer kit (Clontech, Palo Alto, CA).

Expression of core, E1, and E2 proteins of the recombinant baculoviruses in Sf9 cells (from *Spodoptera frugiperda*) was analyzed by indirect immunofluorescence. Indirect immunofluorescence was performed as follows: cells were seeded in a flat bottom 96-well plate (Sf9 cells attach after 1 h at 27° C without shaking). When attached, the culture medium was removed and washed once with ice-cold PBS x 1. Cells were fixed on ice with freshly prepared ice-cold methanol/acetone (50:50) for 2 min; fixation solution was then removed and washed 3 times with ice-cold PBS x 1. Cells were incubated with PBS x 1 containing 0.25% Igepal CA-630 (or NP-40) for 15 min on ice; detergent solution was removed and washed 3 times with ice-cold PBS x 1. Cells were incubated with PBS x 1 containing primary antibody (1/100) plus 0.1% Tween-20, 1% BSA and 0.02% sodium azide for 1 h at room temperature with gentle shaking. Cells were washed 3 times with PBS x 1 and incubated in the dark with FITC-coupled goat anti-mouse antibody (1/250) in the same buffer for 45 min. The cells were washed 3 times with PBS x 1 and analyzed with a fluorescence microscope.

Example 2. First Method of Purification - HCV Structural Proteins (HCV-SP)

Sf9 cells were grown at 27° C in Sf900 medium (Gibco-BRL/Life Technologies, Gaithersburg, MD) and were infected with recombinant baculovirus at multiplicity of infection (MOI) of 5 in a 500-ml Erlenmeyer flask, and cells were harvested at 3 days post-infection. All purification steps were carried out at 4° C on ice. Cells were harvested (3,000 rpm for 15 min), washed once in 10 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM CaCl₂ (TNC) buffer containing 1 mM Pefabloc SC and a cocktail of EDTA-free protease inhibitors (Roche, Indianapolis, IN), and finally resuspended at 1×10^7 cells/ml in TNC buffer containing 0.25% digitonin and protease inhibitors (cf. above). Cells were homogenized, and placed on ice for 4 hr with gentle agitation,

and centrifuged at 30,000 x g for 45 min. The supernatant was collected, precipitated with 10% PEG 8000 and 0.15 M NaCl for 2 hr, and pelleted at 10,000 rpm for 30 min at 4° C. The pellet was resuspended in TNC buffer and briefly homogenized. 100-200 µl of homogenized suspension was applied onto a 10.5 ml of 20-60% sucrose gradient and centrifuged at 156,000 x g for 16 hr. Fractions, 1 ml, were collected from the top of the tube and were tested for E1, E2 and core proteins by ELISA and western blot. Fractions containing Bac.HCV-S proteins (HCV-SP) were pooled, diluted with TNC buffer and pelleted at 100,000 x g for 3 hr. Pellets containing HCV-SP were resuspended in TNC buffer and stored at -70° C. Protein concentration was determined using Coomassie Plus protein assay reagent (Pierce, Rockford, IL) with BSA as the protein standard. Similar methods were used to express and purify proteins produced with Bac.HCV-S/p7 (HCV-SP/p7).

Example 3. Characterization of HCV-SPs

The fractions collected from the sucrose gradients, as described in Example 3, were analyzed for the presence of E1, E2 and core proteins by both ELISA and Western blot. E2 ELISA was performed as described: a 96-well plate was coated with 100 µl (20 µg/ml in PBS) of GNA (lectin from *Galanthus nivalis*) at 37° C for 3 hr. To prevent non-specific binding, 150 µl of 4% goat serum (in 5% skim milk-PBS) was added and incubated for 3 hr at room temperature. Samples containing HCV-SPs were diluted in 5% skim milk-PBS, added to each well and incubated at 4° C, overnight. Anti-E2 monoclonal antibody (mAb AP33, 100 µl, 6 µg/ml) was added and plate was incubated for 3 hr at 37° C. Peroxidase labeled goat anti-mouse IgG (at a dilution of 1/1000) was then added and incubated for 1 hr at 37° C. Bound antibodies were detected by adding ABTS Microwell Peroxidase Substrate System and measured on an ELISA reader at an optical density of 405 nm (OD 405 nm). Plate was washed six times with PBS between each step and, after addition of anti-E2 mAb, with PBS-0.05% Tween 20. All dilutions were made in PBS containing 5% skim milk.

ELISA results (Figure 2A) showed E2 reactivity was detected in two peaks: the lighter density (fractions 1-3) correspond to a buoyant density of 1.14-1.18 g/ml, and heavier density (fractions 8-9) correspond to buoyant densities of 1.2-1.25 g/ml. Western blot analysis (Figure 2B) using anti-E2 mAb (ALP98) showed a group of major E2 protein bands of ~70 kDa; the core

protein was detected as a band at ~20 kDa. Two major forms of E1 (~33 and ~28 kDa) which reflect the different extent of N-linked glycosylation were also observed (not shown). The E2 protein of HCV-SPs was recognized by conformation-sensitive anti-E2, H2 and H53 mAbs, indicating that the E2 protein of HCV-SPs assume a proper conformation.

Example 4. Cell Binding of HCV-SP and HCV-SP/p7

Binding of the HCV-SP preparations to HepG2 cells was performed as follows: the assays were performed in a U-bottom 96-well plate. All the incubation (on a rocking platform) and centrifugation/washing steps (800 rpm, 5 min) were carried out at 4° C. All dilutions were made in ice-cold binding buffer (TNC buffer containing 1% BSA and a cocktail of EDTA-free protease inhibitors). Adherent cells (HepG2) were washed twice with PBS and detached with 2.5 mM EDTA (in PBS) at 37° C for 10 min prior to use. Cells were rinsed once, resuspended in TNC buffer at 2×10^6 cells/ml and 100 μ l were added to each well. Bac.HCV-SP binding was measured by indirect labeling. 0.125-2.5 μ g of HCV-SPs were incubated with cells for 2 hr, and cells were washed twice to remove unbound proteins. Anti-E2 mAb (AP33) was added and cells were incubated for 1 hr, washed twice, and further incubated for 1 hr with FITC goat anti-mouse IgG (4 μ g/ml). Cells were washed twice, resuspended in 150 μ l of binding buffer, and bound HCV-SP was analyzed by flow cytometry. Nonspecific fluorescence was measured by adding primary and secondary antibodies in the absence of HCV-SPs to cells. The mean fluorescence intensity (MFI) of bound HCV-SPs was determined after subtracting the nonspecific fluorescence value.

As shown in Figure 3A, the binding of the light fraction of HCV-SP occurred in a dose-dependent manner. In contrast, very little binding was observed with the heavy fraction and only at high concentration. In addition, a slight cell toxic effect was observed with this latter fraction. This may be due to the presence of insoluble aggregates that were less recognized by conformational antibodies with ELISA and also with immunoblot. It is known that expression of E1 and E2 glycoproteins in mammalian cells also produced high molecular weight, disulfide-linked aggregates. The binding of HCV-SP and HCV-SP/p7⁻ preparations were compared. Binding was observed with lower concentration of the light fraction of both preparations (Figure

3B), whereas heavy fractions of both HCV-SP and HCV-SP/p7 displayed some binding activity only at the highest concentrations (50 µg/ml).

Example 5. Binding of HCV-SP to Primary Human Hepatocytes, HepG2, and Molt-4 Cells

The ability of HCV-SP to bind various target cells was analyzed by flow cytometry (Figure 4) as in Example 4. Specific HCV-SP binding was found in human hepatic cells (primary human hepatocytes and HepG2 cells) and human T cells (Molt-4 cells), but not in mouse fibroblasts (3T3-L1 cells). The binding of HCV-SP to target cells occurred in a dose-dependent manner in the various cell types (Figure 4B). The results of analysis of the FACS data expressed in percentage of positive cells and mean fluorescence intensity correlated well (Figure 4B).

Example 6. Effect of Calcium and ASGP-R Ligands on HCV-SP Binding

It was tested whether asialation of HCV envelope proteins plays a role in binding of HCV-SP to hepatic cells. The asialo-glycoprotein receptor (ASGP-R) is a C-type (calcium-dependent) lectin that is most commonly found in the liver, although it is also expressed in other tissues. It has been implicated in the clearance of asialo-glycoproteins, i.e. desialated or galactose-terminal glycoproteins, from the circulation by receptor-mediated endocytosis. This receptor consists of a hetero-multimer of two homologous subunits, hH1 and hH2. Each subunit is subdivided into four functional domains: the cytosolic domain, the transmembrane domain, the stalk, and the carbohydrate recognition domain (CRD). The CRD of hH1 requires three calcium ions for proper binding conformation and sugar binding.

The cell binding assay described in Example 4 was used, but modified as described below: cells were pre-incubated with various ASGP-R ligands prior to the addition of HCV-SP. 19S-Tg fraction (Tg = thyroglobulin) contains Tg-dimers (apparent molecular weight of 660 kDa) that have a sedimentation coefficient of 19S by ultracentrifugation. Crude Tg was extracted from bovine thyroid gland and 19S-Tg was purified by column chromatography, as previously described. Orosomucoid and 19S-Tg were incubated with agarose bead-linked neuraminidase, as recommended by the manufacturer (Sigma). After centrifugation, protein concentration of the supernatants containing asialo-orosomucoid and asialo-Tg was determined. All pre-incubation steps were performed for 2 hr at 4° C.

Since ASGP-R binding is calcium-sensitive, it was first asked whether HCV-SP binding to cells occurred in a calcium-dependent manner. The simultaneous removal of calcium from the binding medium together with the addition of 5 mM of the calcium chelator EGTA reduced HCV-SP binding to Molt-4 and HepG2 cells (Figure 5A), results consistent with ASGPR being involved in HCV-SP binding. To test more directly whether the ASGP-R mediates HCV-SP binding to hepatic cells, primary human hepatocytes and HepG2 cells were pre-incubated with several ASGP-R ligands. As shown in Figure 5B, asialo-orosomucoid, a high affinity ligand of the ASGP-R in the liver, inhibited HCV-SP binding to HepG2 cells in a dose-dependent manner. Also, pre-incubation of cells with polyclonal antibody against a peptide of the CRD of hH1 subunit of the ASGP-R resulted in the decreased on HCV-SP binding to HepG2 cells (Figure 5C). This was not observed with preimmune antibody (not shown).

Thyroglobulin (Tg) has been previously reported to bind the ASGP-R. 19S-Tg and its desialated form (asialo-Tg) both inhibited HCV-SP binding to HepG2 cells. At lower concentration, asialo-Tg (0.4 mg/ml) showed the similar or higher inhibitory effect on HCV-SP binding as of 19S-Tg (at 1 mg/ml); desialated Tg is indeed known to have a higher affinity to the ASGP-R than 19S-Tg. Inhibition of binding was not stronger than 60-70%. It is therefore possible that additional binding site of HCV-SP exists that is neither competed by ASGP-R ligands nor sensitive to calcium.

Example 7. Internalization of Radio-Labeled HCV-SP in HepG2 Cells

The question was then asked, after binding to cell surface receptor, HCV-SP could be internalized into human hepatic cells? To do this, Sf9 cells (5×10^8 cells) were infected with Bac-HCV 1a.S (MOI 5) in Sf900 medium containing 0.5% FBS at 27° C for 4 hr. Cells were pelleted, washed once with starvation medium (Sf900 medium minus cysteine and methionine), and then cells were grown in this medium for 24 hr. Then, 2 mCi of Redivue Pro-Mix [35 S]-methionine and cysteine mix were added to the medium and cells were further incubated for 24 hr. The labeling medium was discarded, cells were washed once with Sf900 medium and resuspended in Sf900 medium. HCV-SP (now radiolabeled) were harvested at 3 days post infection. The internalization experiment was then performed as follows: 100 μ g [35 S]-HCV-SP was used/2 $\times 10^8$ cells/well in a 6-well plate. Cells were directly incubated at 37° C for 15, 30, and 60 min. Cells were then harvested, disrupted and submitted to cell fractionation with

sucrose gradient ultracentrifugation, resulting in four fractions corresponding to four membrane-enriched cell compartments. Figure 6 shows that radioactivity was detected in the various compartments even after a short incubation with cells. After 15 min, the increasing amount of radioactivity was observed in all cellular compartments (plasma membrane<micros.mitoch.<SER<RER), suggesting the incorporation of labeled HCV-SP occurred in this order. After 30 min incubation, the amount of radioactivity had reached a steady state in the SER, while it started to decrease in the other intracellular compartments, suggesting that the majority of radio-labeled HCV-SP has reached the smooth endoplasmic reticulum-enriched compartment.

Example 8. Internalization of Dye-Labeled HCV-SP in HepG2 Cells and Co-Localization with ASGP-R GFP-hH1

It was then asked whether ASGP-R was involved in internalization. For this purpose, a clone of stable transfected HepG2 cells expressing a fusion protein between the hH1 subunit of ASGP-R and the green fluorescent protein (GFP-hH1/HepG2 cells) was established. To establish such cells, a GFP-ASGP-R construct was obtained by cloning the PCR amplicon coding for ASGP-R hH1 subunit into pcDNA3.1/NT-GFP-Topo vector (Invitrogen Corporation; Carlsbad, CA). Briefly, cytoplasmic RNA extracted from HepG2 cells was subjected to reverse transcription, then PCR with specific primers to obtain DNA fragments coding for hH1. The pcDNA3.1/NT-GFP-hH1 construct was verified by sequencing for correct sequence and alignment. Transient transfection experiments were performed to confirm the expression of green fluorescent protein (GFP)-hH1 fusion protein. By laser scanning confocal microscopy (LSCM) analysis, a green fluorescent signal was detected in few cells, predominating at the levels of Golgi apparatus and plasma membrane, but was also detected in other cell structures, such as vesicles (not shown). HepG2 cells were then transfected with this plasmid construct using lipofectamine-Plus and after a few days, selection antibiotic was added into the culture medium. Stable transfectants were obtained and the most positive cells were sorted using a Beckman-Coulter system.

Also used were HCV-SP which were labeled with dye. HCV-SP was labeled with 4 μ M CellTracker CM-DiI (Molecular Probes; Eugene, OR) in TNC buffer for 1 hr at 4° C in the dark. Dye-labeled HCV-SP was purified through a 30% sucrose cushion at 100,000 x g for 3 hr; the

pellet was resuspended in TNC buffer containing 1% BSA and protease inhibitors. HepG2 cells were seeded into sterile glass chamber slides one day before the assay. Cells were incubated with labeled HCV-SPs in serum-free DMEM at 4° C for 30 min, followed by incubation at 37° C for 5, 15, or 30 min. Cells were rinsed once with ice-cold PBS and fixed with 4% paraformaldehyde in PEM buffer (80 mM PIPES-KOH, pH 6.8, 5 mM EGTA, 2 mM MgCl₂) for 30 min on ice. Cells were then rinsed three times with PEM buffer and slides were mounted with DAPI/antifade system and kept at dark at 4° C until LSCM analysis was performed. Cells were analyzed with a LSCM (Leica, TCS SP) coupled with a DMIRBE inverted epifluorescent microscope. Wavelengths used to analyze GFP and CM-DiI staining were 499 and 553 nm for excitation, and 519 and 570 nm for emission, respectively.

In the transfected HepG2, without added virus, some GFP signal was visible in the endoplasmic reticulum area, but mostly in the Golgi apparatus area, suggesting that GFP-hH1 subunit was properly glycosylated before targeting to the plasma membrane. Following incubation of cells with CM-DiI-labeled HCV-SP (red), co-localization was analyzed by LSCM. It was observed that, after uptake, this material accumulated in the cell area surrounding the nucleus. Moreover, by superimposing the pictures obtained in green and red channels, it was observed that there was a clear co-localization with recombinant GFP-hH1 (Figure 7). This suggests that HCV-SP not only entered HepG2 cells, but also that it was targeted toward an area surrounding the nucleus, simultaneously with the hH1 subunit of ASGP-R.

Furthermore, as shown in Figure 8, the incubation at 37° C of dye-labeled HCV-SP with GFP-hH1/HepG2 cells was followed by a dose-dependent uptake of the labeled material. The intensity of HCV-SP/p7⁺ uptake was less than that observed with HCV-SP preparation (Figure 8). Finally, no uptake of dye-labeled HCV-SP was observed in a cell line of human thyrocytes (Aro cells) that do not express ASGP-R (data not shown). In addition, using a dye-labeled control preparation obtained by expressing recombinant β -glucuronidase with a baculovirus construct (bac-GUS), no uptake was observed in HepG-2 or HuH-7 cells (not shown), both well known to express ASGP-R at a high level.

Example 9. Binding of HCV-SP to transfected 3T3-L1 cells expressing the human liver ASGP-R subunits

3T3-L1 cells, a cell line of mouse fibroblasts that do not bind HCV-SPs (Figure 9A) was chosen to express the human hepatic ASGP-R (subunit hH1 and hH2). Stable ASGP-R-transfected cells (3T3-22Z) were obtained (Figure 9B) as follows: 3T3-L1 cells were co-transfected with plasmid constructs coding for two full-length subunits of the human hepatic ASGP-R (hH1 and hH2) that have previously been shown to both be targeted to the plasma membrane in HepG2 cells. Briefly, cytoplasmic RNA extracted from HepG2 cells was subjected to reverse transcription, then PCR with specific primers to obtain cDNA fragments coding for hH1 and hH2. To allow simultaneous selection of stable transfected cells expressing both subunits, two mammalian expression vectors (pcDNA3.1-Zeo and -Neo; Invitrogen) were used. Each hH1 or hH2 cDNA fragment was inserted into one distinct vector allowing its expression under the control of a CMV promoter. The correct sequences of both constructs were verified by sequencing. 3T3-L1 cells were then transfected with both constructs simultaneously using Lipofectamine-Plus according to protocol provided by the manufacturer (Gibco-BRL/Life Technologies, Gaithersburg, MD). Three days post-transfection, cells were passed and grown under G-418 and Zeocin selection. Upon several passages, stable 3T3-L1 transfectants were obtained. Total RNA was extracted from those cells and cDNA was synthesized by reverse transcription; PCR experiments were then performed using the same pairs of primers as above. One amplicon was detected for each PCR (hH1 or hH2) in those cells (3T3-22Z); agarose gel analysis showed that each amplicon had the same size as the corresponding amplicon obtained in HepG2 cells, whereas no amplicon was detected in 3T3-L1 parental cells. In addition, a variant was obtained, of full length ASGP-R hH2 subunit lacking part of hH2 cytoplasmic domain (non-functional variant) but is still targeted to plasma membrane in HepG2 cells. Another stable-transfected cell line co-expressing hH1 and the hH2 variant was then established (3T3-24X).

The cells were then tested for HCV-SP binding. As shown in Figure 9C, both HCV-SP preparations (added at low concentration: 2.5-10 $\mu\text{g/ml}$ onto 10^4 cells) bound to the ASGP-R expressing cells in a dose-dependent manner (13.23-44.46% of positive cells). Another clone of ASGP-R-transfected cells (3T3-24X) was established, expressing both hH1 and a variant of hH2 (Figure 9B) that lacks part of its cytoplasmic domain (hH2'); the absence of this domain impairs

cell trafficking of hH2' subunit, but does not affect the binding domain. HCV-SP/p7⁻ preparation also bound to 3T3-24X cells (Figure 9C).

Example 10. Internalization of HCV-SP into transfected 3T3-L1 cells expressing the human liver ASGP-R

Parental 3T3-L1 cells, and cell clones 3T3-22Z and 3T3-24X were used to study whether the expression of ASGP-R, not only allowed non-permissive cells to bind HCV-SP, but also rendered them permissive for HCV-SP internalization. Figure 10A shows that parental 3T3-L1 cells (wild type) did not uptake dye-labeled HCV-SP or HCV-SP/p7⁻. Interestingly, as 3T3-22Z cells do bind both HCV-SP and HCV-SP/p7⁻, only dye-labeled HCV-SP uptake was observed (Figure 10B), but not dye-labeled HCV-SP/p7⁻ uptake (Figure 10A). This correlates with the lesser uptake of HCV-SP/p7⁻ observed in HepG2 cells, in comparison to HCV-SP. Finally, 3T3-24X cells that also bind both HCV-SP and HCV-SP/p7⁻, did not uptake any of the two dye-labeled HCV-SPs (Figure 10A).

Example 11. Second Method of Purification - Heterogeneous HCV-Like Particles (HCV-LP)

Sf9 cells, grown at 27°C in Sf900 medium (Gibco-BRL/Life Technologies, Gaithersburg, MD) were infected with recombinant baculovirus at a multiplicity of infection (MOI) of 5-10, and cells were harvested at day 3 post-infection. All purification steps were carried out on ice. Cells were washed once with ice-cold 10 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM CaCl₂ (TNC) buffer containing 1 mM Pefabloc SC and a cocktail of EDTA-free protease inhibitors (Roche, Indianapolis, IN), and resuspended in TNC buffer containing 0.25% digitonin and protease inhibitors. Cells were homogenized and let sit on ice with gentle agitation and monitored for cell lysis by trypan blue exclusion. Cell lysate was centrifuged to remove nuclei debris and plasma membrane, and the supernatant was pelleted over 30% sucrose cushion. The pellet was resuspended in TNC buffer, and applied onto a 10.5 ml of 20-60% sucrose gradient in SW41 tubes (Beckman) and centrifuged at 100,000x g for 16 hours. One-milliliter fractions were collected from the top of the tube and tested for E1, E2 and core proteins by ELISA and Western blot. Fractions containing HCV-LPs were stored at -70°C. Protein concentration was determined using Coomassie Plus protein assay reagent (Pierce, Rockford, IL) with BSA as the

protein standard. The ultrastructural morphology of HCV-LPs was analyzed by cryoelectron microscopy.

Example 12. Characterization of HCV-LPs

The fractions collected from the sucrose gradients, as described in Example 11, were analyzed for the presence of E1, E2 and core proteins by both ELISA and Western blot, as described in Example 3.

ELISA results (Figure 11A) showed the peak of E2 reactivity was detected in fractions 6 to 8, which correspond to buoyant densities of 1.17-1.22 g/ml. Western blot analysis revealed that these fractions contain E2 protein band at ~70 kDa, three major bands of E1 (~33, 32 and ~28 kDa), and a core protein band at ~21 kDa (Figure 11B). The presence of three bands of E1 protein reflects the different extent of N-linked glycosylation. As analyzed by cryoelectron microscopy, HCV-LPs are vary in sizes (35-49 nm in diameter) (Figure 1C). This size difference is, in part, may be due to the difference in the amount of E1/E2 proteins incorporated into each type of particle (data not shown).

Example 13. Binding of HCV-LPs to Human Hepatic and Lymphoid Cell Lines

Using HCV-LPs, as isolated in Example 11, a cell-based binding assay in two formats has been developed. Both binding assays were performed at 4°C in 100 µl of TNC buffer containing 1% BSA. For the first, indirect binding method, anti-E2 mAb was used to detect HCV-LP binding to cells. In this method, cells were incubated with various amounts of HCV-LPs for 2 h, washed twice, and cells were incubated with anti-E2 mAb (AP33) (15 µg/ml) followed by FITC goat anti-mouse IgG (4 µg/ml). Cell-bound HCV-LPs was analyzed by flow cytometry. Nonspecific fluorescence was measured by adding primary and secondary antibodies in the absence of HCV-LP to cells. The mean fluorescence intensity (MFI) of bound HCV-LP was determined after subtracting the nonspecific fluorescence value.

In the second method, the HCV-LPs were labeled with a lipophilic (CM-DiI) or nucleic acid dye (SYTO 12) and used for direct binding assay. To label, HCV-LPs were incubated with 5 µM of SYTO-12 or 1-5 µM of CM-DiI in TNC buffer at 4°C for 15 min and re-purified

through a 30% sucrose cushion to remove free dye. Cells were incubated with increasing concentrations of labeled HCV-LPs for 1 h at 4°C, washed twice, and bound (B) HCV-LPs was analyzed directly by flow cytometry. As a control for the direct binding assay, fraction prepared identically from control Bac-GUS-infected cells was labeled with the dye and used for binding assay. The MFI values of total binding (T) were based on the MFI of 100 µg/ml HCV-LPs in the absence of cells. Scatchard plot was analyzed as described.

The ability of HCV-LPs to bind various target cells was analyzed by flow cytometry first using the indirect method. As shown in Figure 12, HCV-LPs bound to hepatic (PHH, HepG2, HuH7, and NKNT-3) and T cell (Molt-4) lines, but not to thyroid cells (Aro). HCV-LPs also bound to human B cell line (Daudi), but not to Hela cells, mouse fibroblast (3T3-L1) and mouse mastocytoma cell line P815 (data not shown). Binding of HCV-LPs to target cells occurred in a dose-dependent manner and saturable (Figure 13A and B). HCV-LPs bound to Molt-4 and NKNT-3 cells with higher affinity than that to PHH and HepG2 cells.

Pretreatment of cells with 0.25% trypsin abolished HCV-LPs binding (data not shown), suggesting that binding of HCV-LPs to cells is mediated by cellular surface protein(s). HCV-LPs binding to cells occurred, at least partially, in a calcium-dependent manner as addition of 5 mM EGTA reduced this binding (Figure 13C).

To estimate the affinity of HCV-LP binding to hepatic and lymphoid cells, Scatchard plot analysis was performed. Using the direct binding assay with SYTO 12-labeled HCV-LPs, it was demonstrated the presence of a biphasic binding with high and low affinities to NKNT-3 and Molt-4 cells. The high affinity binding site has a dissociation constants (K_d) of ~1 µg/ml, while the lower affinity binding site has a K_d of ~50-60 µg/ml (Figures 13 D and E).

Example 14. Inhibition of HCV-LPs Binding by Anti-E1 and Anti-E2 mAbs

To test whether binding of HCV-LPs to cells is mediated through the envelope proteins, E1 and E2, the following study was done. SYTO 12-labeled HCV-LPs were pre-incubated with increasing amounts of anti-E2 (AP33, ALP98), anti-E1 (A4), or isotype (control) IgG for 2 h at 4°C. The HCV-LPs-antibody mixtures were then incubated with cells for 1 h. After washing, cell-bound HCV-LPs were analyzed. The results (Figure 14) show that pre-incubation of SYTO

12-labeled HCV-LPs with anti-E2 (AP33 or ALP98), anti-E1 (A4) mAbs inhibited HCV-LP binding to cells in a dose-dependent manner. On the other hand, neither isotype control IgG nor anti-core (data not shown) had any effect.

Example 15. Effect of CD81 on HCV-LP Binding

While HepG2, HuH7, NKNT-3 and Molt-4 cells all bound to HCV-LPs, significant differences in their CD81 expression existed. As assessed by RT-PCR, the strain of HepG2 cells used lacks CD81 expression, while others express CD81 (data not shown). Hence, HCV-LPs bound to HepG2 cells in a CD81-independent manner. Recombinant CD81 failed to inhibit HCV-LP binding to HuH7 cells, although it partially inhibited HCV-LPs binding to Molt-4 and NKNT-3 cells (Figure 15A). Furthermore, anti-human CD81 mAb that had been shown to block truncated E2 binding to cells did not have any significant effect on HCV-LP binding to HuH7 and Molt-4 cells (Figure 15B).

Example 16. Effect of VLDL, LDL, and HDL on HCV-LP Binding

Molt-4 cells which express LDL receptors and have been used previously to characterize HCV-cell interaction were used in this study. HCV-LPs were pre-incubated with the lipoproteins before being added to cells in the indirect binding assay. It was found that LDL inhibited HCV-LPs binding when added simultaneously to cells (Figure 16A), while pre-incubation of HCV-LPs with LDL completely abolished their binding to cells (Figure 16B).

Previous study has proposed that association of HCV virions and β -lipoproteins in the plasma may mask the virions from circulating antibodies, and at the same time, represent one mechanism of HCV entry into cells, i.e. through the LDL receptor. There are two explanations for this finding. LDL may bind to the HCV-LPs and inhibit their binding to cells; alternatively, LDL binding to HCV-LPs may hinder the accessibility of HCV-LPs to anti-E2 mAb used in this indirect binding method. To distinguish between these two possibilities, the direct binding method was used. Cells were incubated with SYTO 12-labeled HCV-LPs. As shown in Figure 16A, pre-incubation of labeled-HCV-LPs with LDL reduced their binding to Molt-4 cells by >50%. A similar phenomenon was observed when HCV-LPs was pre-incubated with VLDL or HDL. However, when cells were pre-incubated either with VLDL, LDL or HDL before the

addition of HCV-LPs, HCV-LPs binding was slightly increased (Figure 16C). Altogether, these results indicate that pre-incubation of HCV-LPs with VLDL, LDL and HDL resulted in lipoprotein-HCV-LPs complex that inhibited HCV-LP binding to cell. Second, the increased HCV-LP binding after pre-incubation of cells with these lipoproteins implied that HCV-LPs can also interact with cell-bound VLDL, LDL, or HDL, in addition to other cell surface molecule(s). This was confirmed by the inability of two anti-LDL-R antibodies to significantly block HCV-LP binding (Figure 16C).

Example 17. Internalization of Labeled-HCV-LPs by Hepatic Cells

It was examined whether binding of HCV-LPs to cells can be followed by entry. HuH7 and NKNT-3 cells were incubated with CM-DiI or SYTO-labeled HCV-LPs at 4°C for 30 min, followed by incubation at 37°C for various time points. The specificity of internalization process was determined by pre-incubating dye-labeled HCV-LPs with anti-E1 and anti-E2 antibodies before added to cells. As a negative control, cells were incubated with CM DiI- or SYTO-labeled preparation from cells infected with Bac-GUS. Alternatively, Aro cells were incubated with dye-labeled HCV-LPs. Cells were fixed with 4% paraformaldehyde, washed and mounted with DAPI/antifade system. Cells were imaged on a Leica TCS SP laser-scanning confocal microscope mounted on a DMIRBE inverted epifluorescent microscope. SYTO and CM-DiI fluorescent dyes were excited by a 499 nm and 553 nm, respectively, laser lines from a water-cooled argon laser (Coherent Laser, CA). SYTO and CM-DiI fluorescence emissions were monitored at 519 and 570 nm, respectively.

Figure 17 showed the internalization of CM-DiI-labeled HCV-LPs by HuH7 cells as analyzed by laser-scanning confocal microscopy. This internalization was temperature-dependent as only a weak signal was detected at 4°C (Figure 17A), while following incubation at 37°C, a higher intensity of dye-labeled HCV-LPs was observed in the cytoplasm surrounding the nucleus (Figure 17B). In contrast, HuH7 cells did not uptake CM-DiI-labeled Bac-GUS preparation after incubation at 37°C (Figure 17C). Aro cells that did not bind HCV-LPs were used as a negative control to assess the specificity of the internalization of HCV-LPs. The results showed that, Aro cells did not uptake labeled HCV-LPs (data not shown).

The ability of NKNT-3 cells to internalize SYTO labeled-HCV-LPs was shown in Figures 17D to H. Following incubation at 4°C, a weak signal of SYTO-labeled HCV-LPs was found mostly surrounding the cell surface (Figure 17D). The incorporation of dye into the cytoplasm increased when cells were incubated at 37°C for 30 min (Figure 17E). It was also observed that SYTO dye was found in the nucleoli, which is presumably due to the staining of the RNA-containing nucleoli by the dye released from HCV-LPs after entry. NKNT-3 cells reacted poorly with SYTO-labeled Bac-GUS preparation (Figure 17F). To assess whether specific antibodies could inhibit HCV-LPs entry into cells, labeled HCV-LPs were pre-incubated with anti-E1/-E2 antibodies for 2 h at 4°C. HCV-LPs (in the absence of antibodies) and after pre-incubation with antibodies were then incubated with cells for 15 min at 37°C. While the control HCV-LPs were internalized by cells (Figure 17G), pre-incubation with antibodies significantly reduced the incorporation of labeled HCV-LPs (Figure 17H). These data suggest that E1 and E2 protein mediate HCV-LPs binding and subsequently, their entry into cells.

Example 18. Third Method of Purification - Homogeneous HCV-Like Particles (HCV-LP)

Sf9 insect cells were grown in Sf900 II medium containing antibiotics-antimycotics at 27° C (125 rpm) in sterile Erlenmeyer flasks with a volume ratio < 1/3. To amplify HCV recombinant baculovirus stock, insect cells were infected at an MOI 0.1 (Virus titer was determined by BAC-Pak Rapid Titer kit) and harvested at 3 days post-infection. Supernatant containing baculovirus was concentrated by centrifugation at 48,000 x g for 2 h at 4° C (SW28 rotor, Beckman). The virus pellet was resuspended in Sf900 medium and stored in small aliquots at - 70° C.

The infection protocol for small-scale preparation was as follows: Sf9 cells were infected with recombinant baculovirus at an MOI of 1 or 10/cell. To ensure that cells were infected simultaneously, cells were resuspended in a small volume of medium containing the inoculum (~10⁸ cells/5 ml) for 1 h in 125 ml sterile Erlenmeyer flask. After 1 h, without removing the inoculum, fresh Sf900 II medium (containing 0.5% fetal bovine serum and antibiotics-antimycotics solution) was added to reach a density of 2.5-5 x 10⁶ cells/ml. Cells were grown at 27° C (125 rpm) and harvested after 2, 3 or 4 days incubation.

The following steps in the cell lysis protocol were performed either on ice or at 4° C: Sf9 cells were centrifuged into a pellet by rapid centrifugation (3,500 rpm for 1-2 min, without

brake) and culture medium was removed. The volume of the pellet was measured and the term "volume" in the following steps refers to pellet volume. Cells were rinsed by suspending them once in 20 volumes of ice-cold PBS x 1, then pelleted by rapid centrifugation (cf. above) and supernatant was removed. The cells were resuspended by brief vortexing or gentle pipeting in 10 volumes of ice-cold glycerol buffer (50 mM Hepes-NaOH, pH 7.4, containing 5% glycerol, 2 mM EGTA and 2 mM EDTA) and incubated on ice for 30 min; gently swirling the solution by inverting the tube once or twice every 5 to 10 min.

Cells were centrifuged at high speed to pellet them (with glycerol, this sometimes required maximum speed for 1 min or more); pellet volume increased by about 50%; this step was critical to remove any excess of glycerol. The supernatants were removed and the tube walls were carefully rinsed with 2 volumes of ice-cold hypotonic buffer (10 mM Hepes-NaOH, pH 7.4, containing 1 x protease inhibitor cocktail, 2 mM EGTA and 2 mM EDTA) without resuspending the pellet. Then the liquid used to rinse the tubes was removed (if necessary centrifugation was briefly done again). Cells were resuspended (no vortex, no pipeting) in 2 to 6 volumes (depending on percentage of glycerol used above) of ice-cold lysis buffer (hypotonic buffer containing 0.25% digitonin) and incubated on ice for 15 min; gently swirling the solution every 5 min. The cell lysate was centrifuged at 1,500 x g for 5 min to remove cell nuclei and debris. The lysate from this step was centrifuged at 30,000 x g (15,000 rpm, SW28, Beckman) for 30 min to remove membranes. The lysate from this step was then centrifuged at 100,000 x g for 3 h (28,000 rpm, SW28) through 10 ml of 30% sucrose cushion to pellet VLP; [rate zonal gradient: make continuous sucrose gradient: 0.75 ml of each 20, 30, 40, 50, 60 and 66% sucrose and incubate at 37° C for 1 h, then cool on ice]. The pellet was gently resuspended in TNC buffer (50 mM Tris-HCl, pH 7.4, containing 150 mM NaCl and 1 mM CaCl₂) plus protease inhibitor cocktail with potter (0.5 ml glass/teflon homogenizer [1 ml for maxipreps]) without foaming.

The resuspended pellet was then subjected to equilibrium centrifugation as follows: less than 0.3 ml of sample was loaded on the top of a 20-60% sucrose gradient: 0.75 ml of each 20, 30, 40 and 50% sucrose, and 1.5 ml of 60% sucrose (for 5 ml tubes of SW55, Beckman). Centrifugation was at 100,000 x g (slow acceleration, without brake) for 18 h. One-half ml fractions were collected from the top of the gradient. Bands are visible from fraction 5 to 7. Protein concentration was determined using Coomassie Plus protein assay reagent with BSA as

the protein standard. Figure 2 shows plots of protein concentration vs. gradient fraction number for infections at 1 and 10 MOI for harvest of infected cells at 2, 3 and 4 days post-infection. Figure 3 shows SDS-PAGE and Western Blot analysis of gradient fractions 3-9 of HCV-LP from harvest of cells infected at an MOI of 10 and harvested 3 days post-infection. The Western Blots were probed with monoclonal antibodies specific for E2 (ALP98), E1 (A4) and the core (C1).

Alternatively, equilibrium centrifugation was performed by centrifuging on the top of a preformed sucrose gradient (cf. above) at $100,000 \times g$ for 2 h 30 (slow acceleration without brake) or using a SW41 rotor (Beckman), the 20-60% sucrose gradient is as follows: 1.5 ml of each 20, 30, 40 and 50% sucrose, and 2.5 ml of 60% sucrose (10.5 ml tubes). Less than 0.5 ml sample was loaded and centrifuged at $100,000 \times g$ (slow acceleration, without brake) for 18 h. Collect 1 ml fractions from the top.

The virus was then collected from the collected gradient fractions by centrifuging the fractions at $100,000 \times g$ (33,000 rpm, SW55 with brake) through 1.5 ml of 30% sucrose cushion to pellet purified VLP for 90 min at $4^{\circ} C$.

Example 19. Characterization of purified particles

Several aspects of the HCV-LP obtained with this method were analyzed: yield of HCV-LP containing fractions (total protein concentration/ml culture), biophysical properties, immunoreactivity of HCV-LP (Western Blot) and its ultrastructure (by cryoelectron microscopy analysis).

Yield: With 30 ml culture (10^8 cells), a maximum protein concentration of 1.2 mg/ml was obtained in the fractions with a total of ≈ 2.2 mg protein containing core, E1 and E2 proteins.

Biophysical properties: Following sucrose gradient centrifugation, HCV-LP was found at buoyant densities of 1.15-1.18 g/ml (Figure 18A).

Immunoreactivity: The fractions collected after sucrose gradient centrifugation were analyzed by Western Blot using specific anti-core, anti-E1, and anti-E2 monoclonal antibodies. The result showed that fractions 5-7 exhibited very strong reactivity to all anti-structural protein antibodies tested (Figure 18B).

Cryoelectron microscopy: The HCV-LP preparation was so examined and homogenous double-shelled particles of ~50 nm in diameter were observed. In addition, this preparation was 'clean' from impurities.

Example 20. Binding of HCV-LP to Target Cells

HCV-LP have been tested for its ability to bind to target cells. Human hepatic cells (HuH7) and kidney cells (293) were obtained from American Type Culture Collection. An immortalized human hepatocyte cell line (NKNT-3) and a replication-deficient recombinant adenovirus (Ad) that express the Cre recombinase tagged with a nuclear localization signal (AdCANCRe) was a gift from I.J. Fox (Omaha, NE). Differentiation of NKNT-3 cells to mimic normal primary hepatocytes was achieved by transduction with AdCANCRe followed by selection with G418 (Ad-NKNT-3) with a slight modification. Cells were grown in Chee's Modified MEM containing 5% fetal bovine serum and were analyzed for HCV-LP binding at 3 days post-transduction. HCV-LP was directly labeled with SYTO-12 (nucleic acid dye) according to the manufacturer's protocol. Briefly, HCV-LP were incubated with 5 μ M of SYTO-12 in TNC buffer at 4°C for 15 min and re-purified through a 30% sucrose cushion to remove free dye. 2×10^5 cells were incubated with 2.5 μ g of SYTO 12-labeled HCV-LP in 50 μ l TNC buffer containing 1% BSA and a cocktail of EDTA-free protease inhibitors, for 1 hr at 4°C. Cells were washed once with PBS, detached with 0.25 mM EDTA (in PBS) for 10 min at 37°C, and resuspended in binding buffer. After washing, cell-bound HCV-LP were analyzed by flow cytometry. Figure 19 shows the results. For each cell type, the histogram shows cells in the absence of HCV-LP (gray graph) and after incubation with HCV-LP (black graph). The results showed that HCV-LP bind to HuH-7, NKNT-3 and HEK-293 cells in a dose-dependent manner.

Example 21. Inhibition of HCV-LP Binding to Cells by Anti-E2, -E2 and -Core Antibodies

SYTO 12-labeled HCV-LP were pre-incubated with 20 μ g/ml of anti-E2 (ALP98), anti-E1 (A4), or anti-C mAbs for 2 h at 4°C and were then incubated with Ad-NKNT-3 cells for 1 h (Figure 5, open graph). As control, cells were incubated with HCV-LP in the absence of antibodies (Figure 20, closed graph). After washing, cell-bound HCV-LP were analyzed by flow

cytometry. The inhibition of HCV-LP binding to cells by the anti-E1 and anti-E2 antibodies suggest that binding of HCV-LP to the cells is likely mediated through the envelope proteins E1 and E2. Anti-core antibodies had much less of an effect on HCV-LP binding to cells.

Example 22. Effect of Lipoproteins on HCV-LP Binding to Cells

NKNT-3 cells were transduced with with recombinant AdCANCRe. HCV-LP binding was performed at 3 days post-transduction using 2×10^5 cells incubated with 1.5 or 2.5 μ g of SYTO 12-labeled HCV-LP (Figure 21, closed bar) for 1 hr at 4°C, and analyzed by flow cytometry. (A, B) NKNT-3 or Ad-NKNT-3 cells were pre-incubated with apolipoprotein E4 for 2 hr at 4°C before adding HCV-LP and incubating for another 1 hr (striped bar). (C, D) Cells were pre-incubated with 0.5 mg/ml of LDL (hatched or striped bar) or without (closed bar), as a control, before adding dye-labeled HCV-LP. Alternatively, HCV-LP were pre-incubated with LDL before adding to cells (open bar). (E, F) Cells were pre-incubated with 0.5 mg/ml of HDL before adding dye-labeled HCV-LP (hatched bar); as a control, cells were incubated with HCV-LP in the absence of LDL (closed bar). Alternatively, HCV-LP were pre-incubated with HDL before adding to cells (open bar).

Example 23. Effect of AGSP-R Ligands on HCV-LP Binding to Cells

NKNT-3 cells were used as is or transduced with recombinant AdCANCRe. (Figure 22A) Cells were then pre-incubated with rabbit anti-ASGPR antibody for 2 hr at 4°C before adding SYTO 12-labeled HCV-LP (striped bar). As control, cells were incubated with HCV-LP in the absence of anti-ASGP-R antibody (closed bar). (Figure 22B) Cells were pre-incubated with 0.5 mg/ml of Tg 19S for 2 hr at 4°C before SYTO 12-labeled HCV-LP was added (striped bar). Alternatively, HCV-LP were pre-incubated with Tg 19S for 2 hr at 4°C before added to cells (open bar).

CLAIMS

We claim:

1. A method for isolating a purified preparation of hepatitis C virus-like particles comprising:
 - a) infecting insect cells with one or more baculoviruses encoding one or hepatitis C virus proteins;
 - b) lysis of the infected cells to yield a lysate;
 - c) addition of a solution of polyethylene glycol to the lysate to form a precipitate;
 - d) collection of the precipitate
 - e) optional purification of virus-like particles from the precipitate by gradient centrifugation.

2. A method for isolating a purified preparation of hepatitis C virus-like particles comprising:
 - a) infecting insect cells with one or more baculoviruses encoding one or hepatitis C virus proteins;
 - b) lysis of the infected cells to yield a lysate;
 - c) centrifugation of the lysate through a sucrose cushion;
 - d) optional purification of virus-like particles from the precipitate by gradient centrifugation.

3. A method for isolating a purified preparation of hepatitis C virus-like particles comprising:
 - a) infecting insect cells with one or more baculoviruses encoding one or hepatitis C virus proteins;
 - b) contacting the infected cells with a hypertonic solution;
 - c) contacting the infected cells with a hypotonic solution;
 - d) lysis of the infected cells to yield a lysate; and
 - e) optional purification of virus-like particles from the precipitate by gradient centrifugation.

4. The purified preparation of hepatitis C virus-like particles obtained from the methods of claims 1, 2 or 3.

5. A method of detecting antibodies in a subject reactive with hepatitis C virus comprising:

- a) contacting a sample from the subject with the preparation of hepatitis C virus-like particles of claim 4;
- b) detecting complexes formed between antibodies and the hepatitis C virus-like particles.

6. A method of screening substances for their ability to inhibit binding of hepatitis C virus to cells comprising:

- a) contacting a preparation of hepatitis C virus-like particles with cells capable of binding hepatitis C virus in the presence of the substance; and
- b) assaying the cells for the presence of bound virus.

7. A method for treating individuals for hepatitis C virus comprising administering substances that interfere with binding of hepatitis C virus to cells.

8. A kit for use in detecting hepatitis C virus, antibodies reactive with hepatitis C virus, or substances that interfere with binding of hepatitis C virus to cells comprising:

- a) cells with one or more types of receptors to which hepatitis C virus is capable of binding; and
- b) a purified preparation of hepatitis C virus-like particles obtained from the methods of claims 1, 2 or 3.

9. The kit of claim 8 wherein the receptors are asialoglycoprotein receptors.

10. A pharmaceutical composition for induction of an immune response in an individual comprising a purified preparation of hepatitis C virus-like particles.

11. A pharmaceutical composition for induction of an immune response in an individual comprising cells expressing MHC class I or class II molecules and one or more proteins encoded by a hepatitis C virus genome.




Figure 1





Figure 2





Figure 3









Figure 4




Figure 5




Figure 6




Figure 7






Figure 8


A



B



C



D




Figure 9







Figure 10

A



B



C




Figure 11





Figure 12



Concentration of HCV-LPs (μg)





Figure 13




Figure 14




Figure 15




Figure 16




Figure 17




Figure 19





Figure 20




Figure 21





Figure 22

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.